Compare NBP & SKYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBP | SKYA |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.2M | 150.0M |
| IPO Year | 2019 | 2022 |
| Metric | NBP | SKYA |
|---|---|---|
| Price | $0.86 | $2.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | 490.7K | ★ 2.5M |
| Earning Date | 08-20-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $204,120.00 |
| Revenue This Year | N/A | $35,369.33 |
| Revenue Next Year | N/A | $9.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $0.91 |
| 52 Week High | $5.19 | $3.00 |
| Indicator | NBP | SKYA |
|---|---|---|
| Relative Strength Index (RSI) | 20.57 | 73.44 |
| Support Level | N/A | $1.60 |
| Resistance Level | $1.45 | $3.00 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 3.75 | 81.82 |
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
SkyAI Inc is a digital asset treasury company. It is developing financial technology solutions that combine stablecoin infrastructure and artificial intelligence to provide financial services, educational resources, and financial information to users in Asia, Latin America, and Africa.